首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >SOLID STATE COMPATIBILITY STUDIES BETWEEN MONTELUKAST SODIUM AND LEVOCETIRIZINE
【24h】

SOLID STATE COMPATIBILITY STUDIES BETWEEN MONTELUKAST SODIUM AND LEVOCETIRIZINE

机译:孟鲁司特钠和左西替利嗪之间的固态相容性研究

获取原文
           

摘要

Objective: The aim of this research is to evaluate montelukast (MNT)-levocetirizine (LVZ) incompatibility when they gather in one solid dosage form. Methods: Both drugs and their binary mixture (2:1) (MNT-LVZ) were subjected to the following condition: 25°C/60% RH and 40°C/75% RH for 14 weeks. Samples were withdrawn and analyzed using stability-indicating high-performance liquid chromatography (HPLC) method at time intervals (0, 1, 4, 14 weeks). Further investigations were carried out using differential scanning calorimeter (DSC), Fourier transform infrared (FTIR), and X-ray powder diffraction (XRPD) Result: On the basis of HPLC results, the degradation percentage of both drugs in binary mixtures was <10% indicating no chemical interaction; this was confirmed by all FTIR results except new band 668 cm?1 appeared in the spectrum of the mixture after storing 14 weeks at 40°C/75% RH, revealing possible hydrogen bond formed in the mixture. DSC and XRPD revealed possible physical interaction including phase transformation (release the acid form of montelukast and basic form of levocetirizine and sodium chloride in the medium); this may affect dissolution rate and bioavailability. Conclusion: The results obtained from this research gave an evidence to formulate MNT and LVZ in stable fixed-dose combination for the effective treatment of allergic diseases
机译:目的:本研究旨在评估孟鲁司特(MNT)-左西替利嗪(LVZ)以一种固体剂型聚集时的不相容性。方法:将两种药物及其二元混合物(2:1)(MNT-LVZ)置于以下条件下:25°C / 60%RH和40°C / 75%RH,持续14周。在时间间隔(0、1、4、14周)使用指示稳定性的高效液相色谱(HPLC)方法抽取样品并进行分析。使用差示扫描量热仪(DSC),傅里叶变换红外(FTIR)和X射线粉末衍射(XRPD)进行了进一步研究。结果:根据HPLC结果,两种药物在二元混合物中的降解率均小于10 %表示无化学相互作用;所有FTIR结果都证实了这一点,除了在40°C / 75%RH下储存14周后,混合物光谱中出现了新的668 cm?1带,表明混合物中可能形成氢键。 DSC和XRPD揭示了可能的物理相互作用,包括相变(在培养基中释放孟鲁司特的酸形式和左西替利嗪和氯化钠的基本形式);这可能会影响溶出度和生物利用度。结论:本研究结果为以稳定的固定剂量组合配制MNT和LVZ有效治疗变应性疾病提供了证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号